33 terminated. 33 Phase 2, 6 Phase 3, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 33 | Terminated 33 |
| Phase 3 | 6 | Terminated 6 |
| Phase 1 | 3 | Terminated 3 |
Follow Ischemic Stroke: new trials by email Literature Review of Ischemic Stroke trials Research Report on Ischemic Stroke
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Maimonides Minocycline in Stroke Study Minocycline - Stroke, Acute, Ischemic Stroke | Phase 2 / Phase 3 | Terminated | Maimonides Medical Center | 2 | 2023-11-01 | 2025-12-17 |
| Impact of an Immune Modulator Dimethyl Fumarate on Acute Ischemic Stroke Dimethyl fumarate - Acute Ischemic Stroke | Phase 1 / Phase 2 | Terminated | Xuanwu Hospital, Beijing | 2 | 2021-12-01 | 2023-10-25 |
| N-ACETYLCYSTEINE FOR THROMBOLYSIS IN ACUTE STROKE N-Acetyl cysteine - Stroke, Ischemic | Phase 2 | Terminated | University Hospital, Caen | 12 | 2021-06-16 | 2025-07-25 |
| Penumbral Rescue by Normobaric O2 Administration in Patients With Ischemic Stroke and Target Mismatch ProFile Medical oxygen, Standard of care - Acute Ischemic Stroke | Phase 2 | Terminated | University Hospital Tuebingen | 223 | 2019-08-01 | 2022-09-23 |
| Investigation of Neural Stem Cells in Ischemic Stroke CTX0E03 Drug Product and delivery device, Placebo - Ischemic Stroke, Chronic Stroke | Phase 2 | Terminated | ReNeuron Limited | 15 | 2018-08-31 | 2021-08-13 |
| Tirofiban for Patients Treated With Alteplase Tirofiban, Alteplase - Ischemic Stroke | Phase 2 / Phase 3 | Terminated | Capital Medical University | 30 | 2017-12-16 | 2020-09-09 |
| Dose Finding Study of MCI-186 in Acute Ischemic Stroke Continuous infusion high-dose MCI-186, Continuous infusion low-dose MCI-186, Continuous infusion placebo - Acute Ischemic Stroke | Phase 2 | Terminated | Shionogi | 17 | 2017-11-17 | 2026-07-16 |
| DNS-3379 vs. Placebo in Stroke Rehabilitation DNS-3379, Placebo - Ischemic Stroke | Phase 2 | Terminated | Dart NeuroScience, LLC | 1 | 2017-11-13 | 2018-02-01 |
| Fluoxetine for Visual Recovery After Ischemic Stroke Fluoxetine, Placebo - Acute Stroke, Visual Field Loss | Phase 2 | Terminated | Bogachan Sahin | 17 | 2016-05-01 | 2021-10-13 |
| HT-3951 vs. Placebo in Stroke Rehabilitation HT-3951, Placebo - Ischemic Stroke | Phase 2 | Terminated | Dart NeuroScience, LLC | 61 | 2016-02-01 | 2018-02-01 |
| DLBS1033 for Acute Ischemic Stroke Patients DLBS1033, Placebo - Acute Ischemic Stroke, Partial Anterior Circulation Infarct | Phase 2 / Phase 3 | Terminated | Dexa Medica Group | 80 | 2014-11-11 | 2023-12-12 |
| Proof of Concept (POC) in Patients With Ischaemic Stroke GSK249320 100/mg, Placebo - Cerebrovascular Accident | Phase 2 | Terminated | GlaxoSmithKline | 134 | 2013-05-18 | 2017-11-17 |
| Field Administration of Stroke Therapy-Blood Pressure Lowering Glycerly Trinitrate - Intracerebral Hemorrhage, Ischemic Stroke | Phase 2 | Terminated | University of California, Los Angeles | 4 | 2013-04-01 | 2020-10-29 |
| Hypothermia in Acute Stroke With Thrombolysis Imaging Evaluation of Revascularization IV t-PA and normothermia, IV-tPA and hypothermia - Acute Ischemic Stroke | Phase 2 / Phase 3 | Terminated | University of California, Los Angeles | 6 | 2013-02-01 | 2017-04-13 |
| Feasibility Study of IV Recombinant Tissue Plasminogen Activator (rtPA) vs. Primary Endovascular Therapy for Acute Ischemic Stroke Intravenous Thrombolysis, Endovascular Arterial Reperfusion - Stroke, Ischemic Stroke | Phase 2 | Terminated | Mayo Clinic | 1 | 2013-01-01 | 2016-10-05 |
| The Efficacy and Safety Study of ALbumin Therapy in Acute Ischemic Stroke Human Serum Albumin 20, 0.9 % Normal Saline - Cerebral Infarction | Phase 2 | Terminated | Seoul St. Mary's Hospital | 2 | 2012-09-01 | 2013-12-02 |
| Extending the Time for Thrombolysis in Emergency Neurological Deficits - Intra-Arterial Intra-arterial Clot Retrieval with Solitaire device, intravenous tissue plasminogen activator (tPA) - Ischemic Stroke | Phase 2 | Terminated | Neuroscience Trials Australia | 70 | 2012-06-01 | 2015-04-21 |
| Randomized Controlled Trial of Argatroban With Tissue Plasminogen Activator (tPA) for Acute Stroke Low Dose Argatroban, High Dose Argatroban, rt-PA (alteplase) - Ischemic Stroke | Phase 2 | Terminated | Andrew D. Barreto, MD | 90 | 2011-10-01 | 2017-05-11 |
| Safety of Rt-PA + Transcranial Emission of Low-Energy Lasers for Acute Stroke Recovery Transcranial Laser Therapy - Ischemic Stroke | Phase 2 | Terminated | University of California, San Diego | 12 | 2011-06-01 | 2016-12-05 |
| Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke PF-03049423, Placebo - Ischemic Stroke | Phase 2 | Terminated | Pfizer | 181 | 2010-12-01 | 2016-02-19 |
Showing 20 of 33. Sign in to see all of them.
Stroke (17) · Cerebral Infarction (2) · Ischemia (2) · Brain Diseases (1) · Cerebral Hemorrhage (1) · Cerebrovascular Disorders (1) · Hemianopsia (1) · Hemorrhagic Stroke (1) · Hypothermia (1) · Ischemic Attack, Transient (1) · Paresis (1) · Thrombosis (1) · cyclopia sequence (1)
Cardiovascular Diseases (33) · Central Nervous System Diseases (33) · Nervous System Diseases (33) · Vascular Diseases (33) · Brain Diseases (32) · Cerebrovascular Disorders (32) · Stroke (16) · Pathological Conditions, Signs and Symptoms (7) · Pathologic Processes (5) · Brain Ischemia (3) · Signs and Symptoms (3) · Brain Infarction (2) · Infarction (2) · Ischemia (2) · Necrosis (2)
Standard of Care (2) · Tissue Plasminogen Activator (2) · 3-(4-(2-hydroxyethyl)piperazin-1-yl)-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido(3,4-b)pyrazin-2(1H)-one (1) · Acetylcysteine (1) · Aspirin (1) · Clopidogrel (1) · DLBS 1033 (1) · Dimethyl Fumarate (1) · Edaravone (1) · Fluoxetine (1) · High-Energy Shock Waves (1) · Minocycline (1) · National Institute of Neurological Disorders and Stroke (U.S.) (1) · Niacin (1) · Nitroglycerin (1)
Dart NeuroScience, LLC (2) · ImaRx Therapeutics (2) · University of California, Los Angeles (2) · ARCA Biopharma, Inc. (1) · Andrew D. Barreto, MD (1) · Bogachan Sahin (1) · Capital Medical University (1) · Codman & Shurtleff (1) · Columbia University (1) · Daiichi Sankyo (1) · Dexa Medica Group (1) · GlaxoSmithKline (1) · Henry Ford Health System (1) · Hospices Civils de Lyon (1) · Maimonides Medical Center (1)
United States (19) · France (6) · Germany (5) · Canada (4) · Belgium (3) · Australia (2) · China (2) · New Zealand (2) · South Korea (2) · Spain (2) · Austria (1) · Bulgaria (1) · Czechia (1) · Finland (1) · Hungary (1)
Andrei Alexandrov, MD (1) · Andrew Barreto, MD (1) · Andrew N. Russman, D.O. (1) · Aneesh B Singhal, MD (1) · Bernadette Boden-Albala, DrPH (1) · Bryan Due, Ph.D. (1) · Carlos Molina Cateriano, MD (1) · Curtis Benesch, MD, MPH (1) · David S Liebeskind, MD (1) · Diah H Soeryaningtias, Sp.S, MD (1) · Dian Cahyani, Sp.S, MD (1) · Dodik Tugasworo, Sp.S(K), MD (1) · Gotot S PW, Sp.S, MD (1) · Hanindia R. Prabaningtyas, Sp.S(K), MD (1)
PMID 20634684, PMID 24207098, PMID 25671797, PMID 25803346, PMID 26069259, PMID 26738812, PMID 28228578, PMID 28507269, PMID 29312109, PMID 33230035, PMID 34726532, PMID 34813082, PMID 34906976, PMID 35130557, PMID 36166771, PMID 36289001, PMID 37515459, PMID 38419030, PMID 41541089
2017 (1), P50NS044148 (1), P50NS049060 (1), P50NS051343 (1), R01HL080107 (1), R01NS077706 (1)